# Molecular Vision

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/molecular-vision

- Industry: Medical Devices & Equipment
- Headquarters: London, UK
- Website: www.molecularvision.co.uk
- Total disclosed funding: $0.7M
- Latest round: Seed (Aug 31, 2007)
- Investors on record: 1

## About

Molecular Vision is a biotechnology company specializing in advanced diagnostic tools and molecular assays designed for healthcare professionals. The company focuses on precise detection of health conditions to improve patient management.Founded in 2001, Molecular Vision is based in London, UK. The company specializes in the development of innovative biotechnology solutions. Notably, in March 2012, Abingdon Health, a portfolio company of Imperial Innovations, acquired a controlling stake in Molecular Vision. The company has raised EUR 0.50 mn in total funding, with the latest round being a Seed round led by Touchstone Innovations.Molecular Vision specializes in innovative solutions within the biotechnology sector, focusing on products that cater to the needs of healthcare professionals and institutions. The company's core offerings primarily include advanced diagnostic tools and molecular assays that enable precise detection of various health conditions. These products are designed to streamline laboratory processes, enhance accuracy in diagnostics, and provide actionable insights for better patient management. The end users of these services primarily include hospitals, diagnostic laboratories, and research institutions that require reliable testing solutions. Molecular Vision markets its products in key geographical regions including North America, Europe, and parts of Asia, ensuring a broad reach in the global healthcare landscape.Molecular Vision generates revenue through a structured transactional model that includes direct sales to healthcare institutions, partnerships with diagnostic labs, and B2B collaborations with distributors. The company typically engages in long-term agreements with its clients, which may involve subscription-based services for continuous product support and updates. For the year 2021, the company reported revenues of EUR 0 mn. Additionally, the company's EBITDA for 2023 is reported at EUR -395.1.Molecular Vision aims to expand its product line by launching new diagnostic tools and assays by 2023 to meet the evolving needs of healthcare professionals. The company plans to penetrate new markets in Asia and North America within the next three years. The recent Seed funding of EUR 0.50 mn will be utilized to support product development and market expansion initiatives. Additionally, in March 2012, the acquisition by Abingdon Health has positioned Molecular Vision for strategic growth opportunities within the biotech sector.

## Funding rounds

- Seed, Aug 31, 2007, $0.7M — Touchstone Innovations

## Investors

- Touchstone Innovations (https://capitalatlas.ai/funds/touchstone-innovations) — Seed